Genotype 4
Treatment-Naive Patients
All Patients

TABLE 134: SVR GENOTYPE 4 TREATMENT-NAIVE: RELATIVE RISKS AND RISK DIFFERENCE FOR ALL TREATMENT COMPARISONS — RANDOM EFFECTS MODEL

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SOF12 + RBV12	PR48	0.99 (0.10 to 1.82)	–0.46 (–46.72 to 42.33)
SOF24 + RBV24		1.63 (1.18 to 1.84)	32.49 (9.45 to 43.41)
SOF12 + PR12		1.85 (1.57 to 1.95)	44.27 (29.60 to 48.25)
SOF24 + RBV24	SOF12 + RBV12	1.60 (0.91 to 15.18)	30.79 (–8.01 to 78.36)
SOF12 + PR12		1.85 (1.00 to 18.78)	43.32 (–0.27 to 91.57)
SOF12 + PR12	SOF24 + RBV24	1.13 (0.93 to 1.55)	11.12 (–6.05 to 33.72)
Random effect model	Residual deviance	3.976 vs. 4 data points	
	Deviance information criteria	19.486	
Fixed effect model	Residual deviance	3.899 vs. 4 data points	
	Deviance information criteria	19.339	

CrI = credible interval; PR = pegylated interferon plus ribavirin; RBV = ribavirin; RD = risk difference; RR = relative risk; SOF = sofosbuvir; SVR = sustained virologic response; vs. = versus.
Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.